Lenalidomide was the primary drug used for maintenance in this study. Key Findings:
Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. IFM_05-May 2022
The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo. Lenalidomide was the primary drug used for maintenance